Patents by Inventor Mark M. Staveski

Mark M. Staveski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-inflammatory compositions and methods
    Patent number: 7186725
    Abstract: The present invention provides compositions and their use in the treatment of inflammatory diseases caused by T-cell proliferation such as sepsis, inflammatory bowel diseases, autoimmune encephalomyelitis, or lupus. The compositions comprise disubstituted ureas of Formulas I, II, III or IV: R1—NH—CO—NH-Q-R2Formula I: Et-NH—CO—NH-Q-R2:??Formula (II) Et-NH—CO—NH—(CH2)3—NR6R7:??Formula (III) Me2N—(CH2)3—NH—CO—NH-Q-R2.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: March 6, 2007
    Assignee: Genzyme Corporation
    Inventors: Mark M. Staveski, Robert J. Miller, Sharon R. Nahill
  • Anti-inflammatory compositions and methods
    Publication number: 20040180871
    Abstract: The present invention provides compositions and their use in the treatment of inflammatory diseases caused by T-cell proliferation such as sepsis, inflammatory bowel diseases, autoimmune encephalomyelitis, or lupus.
    Type: Application
    Filed: December 23, 2003
    Publication date: September 16, 2004
    Applicant: Genzyme Corporation
    Inventors: Mark M. Staveski, Robert J. Miller, Sharon R. Nahill
  • Alpha acyloxyacetamides for kallikrein and urokinase inhibition
    Publication number: 20040044075
    Abstract: Disclosed herein is a compound represented by Structural Formula (I): 1
    Type: Application
    Filed: May 29, 2003
    Publication date: March 4, 2004
    Applicant: Genzyme Corporation
    Inventors: Mark M. Staveski, Scott F. Sneddon
  • Inha inhibitors and methods of use thereof
    Patent number: 6372752
    Abstract: The invention relates to compounds which inhibit the Mycobacterial enoyl-ACP reductase required for cell wall biosynthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of use of these compounds for treating a bacterial infection in a patient.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: April 16, 2002
    Assignee: Genzyme Corporation
    Inventors: Mark M. Staveski, Scott F. Sneddon, Christopher Yee, Andrew Janjigian
  • Phospholipid-saccharide conjugates
    Patent number: 5354853
    Abstract: Novel phospholipid-saccharide conjugates are produced by the reaction of a phospholipid derivative and an activated saccharide. The resulting conjugates can be used to make liposomes which are target-specific or resistant to degradation in vivo.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: October 11, 1994
    Assignee: Genzyme Corporation
    Inventors: Mark M. Staveski, Barbara Y. F. Wan, Alan E. Walts